Log in

NASDAQ:SNOASonoma Pharmaceuticals Stock Price, Forecast & News

$7.70
-0.20 (-2.53 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.22
Now: $7.70
$8.30
50-Day Range
$4.72
MA: $5.64
$9.70
52-Week Range
$3.33
Now: $7.70
$19.60
Volume247,800 shs
Average Volume371,466 shs
Market Capitalization$13.69 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. It also provides Mondoxyne, a doxycycline-based prescription oral tetracycline antibiotic used as a treatment for acne vulgaris; Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; and Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Petaluma, California.
Read More
Sonoma Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.65 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SNOA
CUSIPN/A
Phone707-283-0550

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.97 million
Book Value$7.89 per share

Profitability

Net Income$-11,800,000.00

Miscellaneous

Employees78
Market Cap$13.69 million
Next Earnings Date7/13/2020 (Estimated)
OptionableNot Optionable

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

How has Sonoma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Sonoma Pharmaceuticals' stock was trading at $4.80 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNOA stock has increased by 60.4% and is now trading at $7.70. View which stocks have been most impacted by Coronavirus.

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, July 13th 2020. View our earnings forecast for Sonoma Pharmaceuticals.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) announced its quarterly earnings results on Thursday, November, 14th. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.27. The firm earned $4.97 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 25.58% and a negative return on equity of 44.11%. View Sonoma Pharmaceuticals' earnings history.

Has Sonoma Pharmaceuticals been receiving favorable news coverage?

News stories about SNOA stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sonoma Pharmaceuticals earned a news impact score of -2.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next few days. View the latest news aboutSonoma Pharmaceuticals.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,300 shares, a decline of 82.4% from the April 30th total of 7,400 shares. Based on an average trading volume of 18,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Sonoma Pharmaceuticals' Current Options Chain.

Who are some of Sonoma Pharmaceuticals' key competitors?

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the following people:
  • Mr. Frederick J. Sandford, CEO, Interim CFO & Director (Age 58)
  • Mr. Marc Umscheid, Chief Operating Officer (Age 50)
  • Dr. Robert Northey, Exec. VP of R&D (Age 62)
  • Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 55)
  • Ms. Victoria Covel, Assistant Controller

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $7.70.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $13.69 million and generates $18.97 million in revenue each year. Sonoma Pharmaceuticals employs 78 workers across the globe.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is www.sonomapharma.com.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.